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Abstract
Isolated distal deep vein thrombosis (IDDVT) accounts for approximately 50% of all patients diagnosed with 
DVT. While the definitive management of patients with proximal deep vein thrombosis is fairly well defined, 
IDDVT remains shrouded uncertainty. The great majority of patients with IDDVT may remain with little or no 
symptoms and have spontaneous resolution of the thrombi. However, a small but significant fraction may show 
proximal thrombus extension and may proceed to cause pulmonary embolism or late deep venous reflux. 
Identification of this subgroup of patients with IDDVT who have a greater propensity for thrombus extension or 
further sequelae remains the cornerstone of individualized management for optimal results.
Key words: deep vein thrombosis, pulmonary embolism, calf vein thrombus, venous 
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Introduction
Systemic anticoagulation remains the standard of care 
in managing proximal deep vein thrombosis (PDVT). 
However, the optimal management of isolated distal 
deep vein thrombosis (IDDVT) remains heavily debated 
and controversial. IDDVT refers to the deep venous 
thrombi occurring in the veins distal to and not involving 
the popliteal vein. These include the tibial and peroneal 
veins as well as the intramuscular venous plexus of 
soleus and gastrocnemius muscles. At present, there 
is no clear consensus among clinicians regarding the 
clinical significance nor the optimal management of 
IDDVT. While some argue the probability of proximal 
propagation, risk of pulmonary embolism (PE) and late 
post-thrombotic syndrome (PTS) in untreated IDDVT, 
others argue that it is primarily a self-limiting benign 
disease and routine treatment is ‘overkill’. Hence, an 
informed precise decision needs to be made regarding 
the management of IDDVT on an individual basis. This 
requires balancing the benefits of avoiding short and 
long-term sequelae by anti-coagulation against potential 
adverse effects of the treatment and economic burden 
of such treatment. This update will attempt to revisit 
the said areas of controversy with a look at the available 
evidence regarding the optimal management of IDDVT.
Epidemiology
The estimated annual incidence of deep vein thrombosis 
(DVT), both PDVT and IDDVT, is approximately 1 in 
1000 adults[1]and recurs frequently. VTE is a complex 
(multifactorial. Among the diagnosed patients with DVT 
and PE, the mean prevalence of IDDVT is estimated 
to be around 50% (20–70%) [1]and recurs frequently. 
VTE is a complex (multifactorial. However, this could 
be a gross underestimate as the majority of patients 
with IDDVT remain asymptomatic and may not present 
to hospital, contributing to under-reporting. The wide 
variability in IDDVT prevalence across the literature is 
attributed to the lack of consensus on reporting the pa-
tient cohort (symptomatic vs asymptomatic and in-pa-
tient vs out-patient). There is further discordance in 
the modality of diagnostic imaging (duplex ultra-sound 
— DUS vs venography) used in the diagnosis of IDDVT. 
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The immediate danger of DVT is the risk of prop-
agation and PE. Therefore, the primary debate re-
garding management of IDDVT revolves around the 
possibility and prevention of PE and associated other 
complications. According to the Center for Disease 
Control (CDC) data in the United States, reviewed 
in 2020, the annual estimated deaths due to PE range 
between 60,000 to 100,000 [2]. Accordingly, PE is seen 
as a bigger contributor to annual mortality than motor 
accidents, breast carcinoma and HIV combined. Wei et 
al. [3] studied the prevalence of IDDVT among hospital-
ized patients with diagnosed DVT and PE (collectively 
referred to as venous thromboembolism; VTE). They 
reported an IDDVT prevalence of 25% among all 
patients with diagnosed PE. In an earlier publication, 
Mattos et al. [4], reported an IDDVT prevalence of 
45% among outpatients and 27% among in-patients 
with confirmed VTE. According to a comprehensive 
study on DUS based DVT diagnoses, Sapp et al. [5] 
reported that simultaneous calf vein DVT is found in 
over 98% of patients diagnosed with PDVT. The inci-
dence of true IDDVT was 54%, indicating that unless 
targeted imaging of the calf veins is performed, over 
half the patients with DVT would be missed and a false 
negative report would ensue.
Diagnosis
Given the high prevalence of IDDVT among patients who 
require hospitalization for VTE, it is imperative that the 
diagnostic modality used in VTE can detect IDDVT in the 
absence of PDVT. However, diagnosis of IDDVT itself 
poses numerous issues. While the vast majority of pa-
tients may remain asymptomatic till proximal thrombus 
extension, even those who do develop symptoms may 
have negative test results due to the reduced sensitivity 
of available diagnostic tools. The Wells prediction rule 
is globally accepted as a pre-test prediction tool in the 
diagnosis of both DVT and PE [6]. However, the accuracy 
of the Wells score in predicting the stand-alone IDDVT 
sub-population is questionable and is considered more 
predictive only in the presence of proximal DVT [7]. 
Sartori et al. [8] found that in IDDVT, the sensitivity of 
Wells predictive rule was only 47% with a specificity 
of only 74%. The corresponding negative and positive 
predictive values for IDDVT were 91% and 20% respec-
tively. Serum D-dimer testing is well established as an 
excellent predictive tool in the diagnosis of VTE, with a 
reported sensitivity > 92% although with a poor spec-
ificity of 45% [9]. However, here again, the usefulness 
of D-dimer in the diagnosis of IDDVT is limited with a 
reported sensitivity of only 84% [8].
DUS is the commonest imaging modality used in the 
confirmation of DVT. The reported sensitivity of DUS in 
the diagnosis of IDDVT is significantly lower than that 
of PDVT. According to a meta-analysis by Goodacre et 
al. [10], the sensitivities of DUS in diagnosing PDVT 
and IDDVT were 96% and 71% respectively. Another 
recent meta-analysis by Zhang et al. [11] actually found 
the sensitivity of DUS in diagnosing IDDVT to be as low 
as 43%. This stark contrast in diagnostic sensitivities of 
available predictive and diagnostic tools for PDVT and 
IDDVT, underlines the issues inherent to the accurate 
diagnosis of IDDVT. 
When using DUS, two common imaging protocols 
have been described for the diagnosis of DVT. The 
first is to perform a limited scan of the proximal veins, 
targeting the popliteal vein and above, where the di-
agnostic sensitivity is very high. However, this targeted 
proximal scan will miss those with IDDVT, that amounts 
to 20–70% of all patients with DVT [12]. While those 
who become positive on the proximal scan are treated 
as for DVT, the ‘high-risk’ patients with a negative scan 
get a repeat scan of the proximal veins after one week. 
This repeat scan is performed with the intention of 
picking any IDDVT which may have propagated to the 
popliteal vein after one week. The rationale behind this 
protocol of imaging is that the PDVT are picked up in 
the first scan and any clinically significant IDDVTs that 
show proximal extension are picked up on the second 
scan. Any such proximal extension of IDDVT is known 
to occur within 5–7 days while the others are known 
to resolve spontaneously, thereby being considered 
clinically insignificant. The second imaging strategy is to 
perform a whole lower limb scan (inguinal ligament to 
ankle) as a single test in an effort to diagnose all DVT 
including IDDVT. While this second strategy allows for 
more IDDVTs to be picked up early, doubts exist regard-
ing its relevance in the absence of proximal extension. 
Furthermore, due to the inherent low sensitivity of DUS 
in detecting IDDVT, a fair number of such patients are 
likely to be missed on the whole limb scan. The lack 
of a clear protocol on DUS for DVT diagnosis has led 
to misinterpretation and variability in reporting among 
individual radiologists, literature and institutions [7].
In 2018, A multi-disciplinary consensus meeting was 
held that included the Society of Radiologists, Society 
for Vascular Ultrasound and American College of Radi-
ologists, to formulate guidelines on DUS for diagnosis 
of DVT [13]. Accordingly, a consensus guideline was 
issued that recommends complete leg scanning from 
inguinal ligament to ankle including tibial and calf veins 
with compression at 2 cm intervals. A consensus was 
also reached regarding the need and place for follow up 
DUS after an initial positive or negative scan (Table 1).
Natural history and complications
The study by Sapp et al. [5] mentioned above also con-
tributed to the growing opinion that all DVT originates in 
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the calf veins. However, it is also postulated that although 
it originates in the calf veins, the majority do not present 
or experience symptoms until the thrombus has already 
propagated to the popliteal vein or proximally [14] 
and most probably resolve spontaneously. Thrombi that 
remain confined to the calf rarely cause leg symptoms 
or symptomatic pulmonary embolism (PE). This results 
in a gross underestimate on the prevalence of IDDVT as 
well as the limitation in the number of studies available 
that deals with IDDVT alone in terms of its sequelae. 
Conversely, there is a different school of thought that 
considers IDDVT as a separate entity and compares it 
with isolated proximal PDVT.
Two major epidemiological studies have been 
published that compared the individual risk factors for 
PDVT and IDDVT; the OPTIMEV study and RIETE regis-
try [15, 16] clinical presentation and estimated 3-month 
survival for each form of VTE were evaluated. Results: 
Of 5889 patients, 426 had PE. Both studies described 
IDDVT associated more with transient risk factors such 
as recent surgical procedure, immobilization, hospitali-
zation, long-distance travel etc. On the contrary, PDVT 
was associated more with chronic risk factors such 
as thrombophilia, malignancy and congestive cardiac 
failure (Table 2).
The vast majority of IDDVT is thought to resolve 
spontaneously without ever causing significant symp-
toms. Although PE with IDDVT in the absence of proxi-
mal propagation has been observed, the risk of PE is dra-
matically increased only after proximal propagation [17]. 
This emphasizes the importance of understanding 
the natural history of IDDVT with possible early rec-
ognition in an effort to minimize proximal extension. 
Although the associated risk is significantly lower than 
with PDVT, the possibility of PE and long-term PTS 
should always be borne in mind during the assessment 
of IDDVT.
Proximal extension
While the vast majority of IDDVT will resolve spontane-
ously without propagation, proximal extension into the 
popliteal veins remains the commonest complication. 
The reported rates of the proximal extension are highly 
variable due to the heterogeneous nature of study 
populations, diagnostic methods and treatment plans 
among study groups. A systematic review by Garry et 
al. [18] studied over 12 papers that discussed the rate 
Table 1. Duplex Ultra Sound scan protocol in the presence of suspected IDDVT. Adapted from Needleman et al. [13]
A. Initial positive whole leg DUS
Clinical condition Recommendation
IDDVT — untreated Repeat DUS in 1 week (or earlier if symptoms progress)
Start treatment if propagated to the popliteal vein
If no propagation at 1 week, repeat scan at 2 weeks
If still no propagation at 2 weeks, no further scan warranted
IDDVT — treated Repeat scan not indicated 
B. Initial negative whole leg DUS
Clinical condition Recommendation
Persistent/worsening symptoms Repeat DUS in 5–7 days
‘High risk’ for DVT (hospitalized, active cancer, post-operative etc.) Consider repeat scan unless another viable aetiology for 
symptoms has been established
Incomplete study/technical failure Repeat scan in 5–7 days
Suspected ileo-caval DVT Specialized imaging (CT/MR venography)
CT: computed tomography; MR: magnetic resonance
Table 2. Risk factors for proximal extension of calf vein 
thrombus
Isolated distal deep vein thrombosis. Risk factors for  
proximal extension
1. Positive D-dimer result
2. Extensive thrombus (> 5 cm in length)
3. Involvement of multiple veins
4. Thrombus diameter > 7 mm
5. Close proximity to the proximal (popliteal) vein
6. Unprovoked DVT
7. Active malignancy
8. Prior history of VTE
9. In-patient status (hospitalized)
68
Acta Angiol, 2020, Vol. 26, No. 2
www.journals.viamedica.pl/acta_angiologica
of proximal extension of IDDVT to be between 0–35% 
(mean 8.9%). Other studies have previously stated 
higher rates of proximal extension around 25%, with-
in 1–2 weeks of presentation [14]and most probably 
resolve spontaneously. Thrombi that remain confined 
to the calf rarely cause leg symptoms or symptomatic 
PE. Hence, the overall rate of proximal extension 
is likely to be between 10–20% of all IDDVT. Further-
more, such proximal extension, if it occurs, is likely to 
occur within the first 1–2 weeks from onset, giving rise 
to the current practice of DUS surveillance for 2 weeks 
in those patients who do not undergo anti-coagulation. 
Identification of the ‘high-risk’ sub-group (Table 2) who 
are likely to have proximal extension allows selective 
ant-coagulation in such patients [19]. 
Pulmonary embolism
The afore-mentioned review by Garry et al. looked at 
over 8 studies that described the risk of PE from IDDVT. 
The reported rates of PE varied between 0–5.8% with 
a mean of 1.4% and is significantly lower compared 
to PDVT [18]. There were no reported PE-related 
deaths in any of the studies. This becomes an important 
determining factor in the decision regarding treatment 
of IDDVT, as the sole basis for treating such patients 
actively as opposed to DUS surveillance is based on the 
immediate risk of PE. Nevertheless, the fact that a small 
fraction of these patients can actually have PE without 
proximal thrombus extension needs to be considered 
in the final decision regarding treatment. 
Recurrent thromboembolism
Another controversial aspect of the management 
of IDDVT is the risk of recurrent VTE compared to 
patients with PDVT. Galanaud et al. [20] compared 
the risk of recurrent VTE in those with PDVT versus 
IDDVT, 3 years after discontinuation of anticoagulation. 
The risk of recurrent DVT was significantly lower in the 
IDDVT group (5.2% vs. 2.7%), while the corresponding 
risk of PE was similar in both groups (1% vs. 0.9%). 
A subgroup analysis found that among those with 
IDDVT, age > 50 years, unprovoked IDDVT and 
involvement of > 1 calf vein were associated with 
a higher risk of recurrence. In a separate study, Sartori 
et al. [21] described that male gender and the presence 
of coexisting active malignancy were associated with 
a higher risk of recurrence after IDDVT. Another sin-
gle-center study that enrolled over 800 patients with 
a first episode of DVT with a mean follow up of 7.6 
years found that IDDVT carried a significantly lower 
risk of recurrent VTE and death compared to IPDVT 
[22]. Table 3 summarizes the risk factors for recurrence 
after IDDVT. 
Post-thrombotic syndrome (PTS)
The risk of PTS after PDVT is estimated to be around 
40% according to the Villata scale [23]. The definitive 
incidence of PTS after IDDVT is not clearly defined. 
Available data suggest that patients with IDDVT expe-
rience far fewer symptoms of PTS compared to those 
with PDVT [24, 25]. Meissner et al. [24] reported that at 
1-year post-diagnosis, 23% of patients with IDDVT still 
had symptoms of pain and swelling in the affected leg. 
This contrasts with PDVT, where up to 54% are found 
to be having residual symptoms at 1 year follow up.
McLafferty et al. [26] studied the long term hae-
modynamic effects following IDDVT and described the 
persistence of deep vein reflux in approximately 1/3 
of patients after 3.4 years of follow-up. Interestingly, 
these changes were seen predominantly in proximal 
venous segments that did not appear to have thrombi 
in the initial DUS. Hence, they postulated the resulting 
reflux was caused by previously unseen occult thrombi 
co-existent with the IDDVT. The CACTUS-PTS study 
(2020) studied the long-term effects, after 6 years 
since the first episode of IDDVT. The results showed 
an overall PTS incidence of 30%, still considerably less 
than the reported values for patients after PDVT [27].
Management
Do all patients with IDDVT require treatment?
While the majority of IDDVT may be self-limiting, the 
preceding discussion shows that a fair proportion of 
patients go on to develop significant complications 
including proximal extension, PE, recurrent VTE and 
late PTS. The said adverse sequelae are commoner in 
a subset of patients who carry ‘high risk ‘characteris-
tics and are left untreated. Hence, a clear distinction 
needs to be made with regards to the identification of 
the said ‘high-risk’ subgroup and initiation of definitive 
treatment over serial DUS surveillance. While there is 
no uncertainty with regards to the treatment of PDVT, 
the decision is often debated in IDDVT due to the po-
tential to do more harm by systemic anti-coagulation. 
Table 3. Risk factors for VTE recurrence after IDDVT
Isolated distal deep vein thrombosis. Risk factors for VTE 
recurrence
1. Age > 50 yrs
2. Unprovoked IDDVT
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The American College of Chest Physicians (ACCP) 
Consensus Conference in 2008 on the management of 
DVT failed to distinguish between IDDVT and PDVT, 
recommending anti-coagulation for a minimum of 
3 months for all patients with DVT [28]. The latest 
ACCP consensus (2016) was more descriptive in its 
plan for PDVT and IDDVT separately [19]. Accordingly, 
it recommends identifying the subgroup of patients 
with IDDVT having ‘high-risk’ of thrombus extension 
(Table 2). These patients, as well as, those having severe 
symptoms are recommended therapeutic anti-coagu-
lation over serial DUS monitoring. Conversely, those 
patients who do not have high-risk factors for thrombus 
extension or and are not severely symptomatic can be 
managed with weekly DUS surveillance. However, both 
these recommendations were classified grade-2C based 
on a weak evidence base. Hence, the exact therapeutic 
approach in a given situation with IDDVT remains heav-
ily debated and leaves room for tremendous individual 
variations in practice. 
Anti-coagulation
Once a decision was made to start anti-coagulation, the 
recommended duration of therapy was a minimum of 
3 months, the same as for PDVT [19]. In the subgroup 
of patients where therapeutic anti-coagulation is not 
commenced and are monitored by serial DUS, initiation 
of treatment is recommended only if there is a proximal 
extension on repeat imaging. The choice of anti-coagu-
lation agent can be based on individual preference and 
feasibility ranging from low molecular weight heparin 
(LMWH), vitamin-K antagonists (warfarin) or one of 
the novel oral anti-coagulants such as rivaroxaban or 
apixaban. The use of compression stockings was not 
routinely recommended in the absence of clear benefit 
in reducing the incidence of PTS. However, it was stated 
that stockings may be used on an individual basis for 
symptom relief [29]singlecentre studies without pla-
cebo control. We aimed to assess the efficacy of ECS, 
compared with placebo stockings, for the prevention 
of PTS. Methods We did a multicentre randomised 
placebo-controlled trial of active versus placebo ECS 
used for 2 years to prevent PTS after a first proximal 
DVT in centres in Canada and the USA. Patients were 
randomly assigned to study groups with a web-based 
randomisation system. Patients presenting with a first 
symptomatic, proximal DVT were potentially eligible 
to participate. They were excluded if the use of com-
pression stockings was contraindicated, they had an 
expected lifespan of less than 6 months, geographical 
inaccessibility precluded return for follow-up visits, 
they were unable to apply stockings, or they received 
thrombolytic therapy for the initial treatment of acute 
DVT. The primary outcome was PTS diagnosed at 
6 months or later using Ginsbergs criteria (leg pain and 
swelling of ≥ 1 month duration. 
What is the optimal duration  
of anti-coagulation?
Due to the relatively poor evidence base behind the 
above ACCP recommendations, individual practices in 
IDDVT management still vary with no clear consensus. 
In his publication, Palareti argues that it is impossible 
to classify patients as asymptomatic IDDVT, as when 
a patient is either referred to or presents to hospital for 
DUS to exclude DVT, he/she is invariably symptomatic [30]. 
He goes on to point out that once IDDVT is diagnosed 
and the diagnosis is informed to the patient, they are 
likely to request some form of treatment, at least 
for symptomatic relief. Hence, in his perspective, 
he recommends treatment for all patients diagnosed 
with IDDVT, with possibly a shorter duration (4–6 
weeks) for those deemed ‘low-risk’. He defines this 
‘low-risk’ subgroup as those having the first episode of 
DVT, provoked by a reversible risk factor and are not 
hospitalized or immobilized. This abbreviated 6-week 
regime has also been recommended by other studies 
who found it as effective as the standard duration of 12 
weeks. Pinede et al. (DOVTAK tria-2001) [31] reported 
no advantage of a 12-week treatment schedule over 
the abbreviated 6-week course. Conversely, Ferrara 
et al. [32] reported a significantly higher rate of prox-
imal thrombus extension with 6 weeks treatment as 
opposed to 12 weeks, especially among those with 
2 or more calf veins involved. A meta-analysis by Franco 
et al. [33] also found a significantly lower rate of VTE 
recurrence among those who were treated for 12 
weeks as opposed to 6 weeks.
The ongoing debate
The question of whether all patients diagnosed with 
IDDVT require anti-coagulant therapy remains one of 
the biggest conundrums in clinical practice. To date, 
there appears to be no final solution with conflicting 
reports from available studies, especially in the ‘low-
risk’ patient with the first episode of IDDVT. Few pro-
spective randomized studies have assessed the efficacy 
of anti-coagulation versus serial DUS and selective 
treatment in IDDVT. 
Schwarz et al. [34] compared 10 days of LMWH with 
3 months of compression therapy versus compression 
therapy alone. The study failed to show any superior-
ity of this short duration LMWH therapy in reducing 
proximal extension or PE among the ‘low-risk’ patients 
with IDDVT. The CACTUS study was a randomized 
double-blind placebo-controlled study looking at 
standard anticoagulation for the same ‘low-risk’ patient 
population [35]. The study had to be prematurely ter-
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minated due to expiry of the study drug before reaching 
the desired level of recruitment and hence carries low 
predictive value. However, from the intention to treat 
analysis, LMWH (nadroparin) for 6 weeks was found 
to be not superior to placebo in preventing proximal 
clot extension or reducing the incidence of PE. The 
treatment arm was actually found to have significantly 
higher rates of major as well as non-major bleeding 
events; risk difference 4.1% (95% CI 0.4 to 9.2; 
p = 0.0255). In a comprehensive meta-analysis by 
Franco et al. [33], the authors reported a significantly 
lower risk of VTE recurrence as well as PE in those 
who were treated with LMWH or oral anti-coagulants 
compared to no treatment with serial DUS only. They 
also reported no significant increase in major bleeding 
episodes among those who underwent anti-coagulation. 
The most recent Cochrane review (2020) by Kirkile-
sis et al. [36] looked at the evidence for anti-coagulation 
against no-treatment or placebo in IDDVT. It concluded 
that the overall rate of VTE and DVT recurrence was 
reduced in those who underwent anti-coagulation 
compared to those in the placebo group or no-treat-
ment group. However, there was no clear advantage 
of anti-coagulation in terms of prevention of PE. As for 
the duration of anti-coagulation, there was no difference 
between groups treated for 6 weeks as opposed to 12 
weeks. Similar to the analysis by Franco and colleagues, 
this also found no significant difference in major bleeding 
episodes with the anti-coagulation. However, there was 
an increased incidence of clinically relevant, non-major 
bleeding.
Conclusions
While therapeutic anti-coagulation remains the bench-
mark in management of PDVT, the place and need for 
anti-coagulation in IDDVT remain a clinical conundrum. 
IDDVT remains an extremely common clinical condi-
tion accounting to approximately 50% of all diagnosed 
patients with DVT. Nevertheless, the number of good 
quality prospective randomized trials studying the place 
of routine anti-coagulation in IDDVT are few. Further-
more, as shown above, findings from these available 
studies are conflicting and do not offer clear guidance 
in formulating a management protocol.
While some studies show a benefit in anti-coag-
ulation for all patients detected with IDDVT, other 
studies concluded that such treatment did not show 
any conclusive benefit over no intervention and possi-
bly carries a higher risk of clinically significant bleeding 
episodes. Given the uncertainty and the lack of quality 
data to offer conclusive evidence, the final decision lies 
with the treating clinician to decide on an individualized 
plan of management. Those with severe symptoms, 
recurrent DVT or considered ‘high-risk’ for thrombus 
extension would benefit by therapeutic anti-coagulation 
over serial DUS monitoring. On the contrary, a careful 
assessment of risk-benefit balance is required in the 
low-risk patient with minimal symptoms where the 
probable benefit of anti-coagulation has to be balanced 
against potential adverse effects such as clinically signif-
icant bleeding. Such low-risk patients with IDDVT are 
possibly best managed by serial DUS screening if the 
logistics for such screening and follow up are feasible. 
Possible treatment of such patients with prophylactic 
dose anti-coagulation rather than therapeutic doses is 
a possible trade-off between minimising the bleeding 
risk and achieving the desired anti-coagulant effect. 
However, such interventions have not yet been tested 




1. Heit JA, Spencer FA, White RH. The epidemiology of venous 
thromboembolism. J Thromb Thrombolysis. 2016; 41(1): 3–14, 
doi: 10.1007/s11239-015-1311-6, indexed in Pubmed: 26780736.
2. https://www cdc gov/ncbddd/dvt/data. Data and Statistics on 
Venous Thromboembolism | CDC.
3. Wei M, Zhu J, Yi X, et al. The prevalence of isolated calf deep 
vein thrombosis in patients with pulmonary embolism. Int Angi-
ol. 2013; 32(5): 465–470, indexed in Pubmed: 23903304.
4. Mattos MA, Melendres G, Sumner DS, et al. Prevalence and 
distribution of calf vein thrombosis in patients with symptomatic 
deep venous thrombosis: a color-flow duplex study. J Vasc Surg. 
1996; 24(5): 738–744, doi: 10.1016/s0741-5214(96)70006-x, 
indexed in Pubmed: 8918317.
5. Sapp B, Craddock G, Sapp J. Patterns and Distribution of Deep 
Vein Thrombus in the Lower Extremity. Journal for Vascular Ultra-
sound. 2018; 39(2): 71–77, doi: 10.1177/154431671503900201.
6. Wells PS, Ginsberg JS, Anderson DR, et al. Use of a clinical 
model for safe management of patients with suspected pul-
monary embolism. Ann Intern Med. 1998; 129(12): 997–1005, 
doi: 10.7326/0003-4819-129-12-199812150-00002, indexed in 
Pubmed: 9867786.
7. Goodacre S, Sutton AJ, Sampson FC. Meta-analysis: The value of 
clinical assessment in the diagnosis of deep venous thrombosis. 
Ann Intern Med. 2005; 143(2): 129–139, doi: 10.7326/0003-
4819-143-2-200507190-00012, indexed in Pubmed: 16027455.
8. Sartori M, Cosmi B, Legnani C, et al. The Wells rule and 
D-dimer for the diagnosis of isolated distal deep vein throm-
bosis. J Thromb Haemost. 2012; 10(11): 2264–2269, doi: 
10.1111/j.1538-7836.2012.04895.x, indexed in Pubmed: 
22906051.
9. Di Nisio M, Squizzato A, Rutjes AWS, et al. Diagnostic accuracy 
of D-dimer test for exclusion of venous thromboembolism: a 
systematic review. J Thromb Haemost. 2007; 5(2): 296–304, 
doi: 10.1111/j.1538-7836.2007.02328.x, indexed in Pubmed: 
17155963.
71www.journals.viamedica.pl/acta_angiologica
Nalaka Gunawansa, Thilina Gunawardena, Management of isolated distal deep vein thrombosis. A persistent conundrum?
10. Goodacre S, Sampson F, Thomas S, et al. Systematic review 
and meta-analysis of the diagnostic accuracy of ultrasonography 
for deep vein thrombosis. BMC Med Imaging. 2005; 5: 6, doi: 
10.1186/1471-2342-5-6, indexed in Pubmed: 16202135.
11. Zhang Y, Xia H, Wang Y, et al. The rate of missed diagno-
sis of lower-limb DVT by ultrasound amounts to 50% or 
so in patients without symptoms of DVT: A meta-analysis. 
Medicine (Baltimore). 2019; 98(37): e17103, doi: 10.1097/
MD.0000000000017103, indexed in Pubmed: 31517841.
12. Heit J, Petterson T, Farmer S, et al. Trends in the incidence 
of deep vein thrombosis and pulmonary embolism: a 35-year 
population-based study. Blood. 2006; 108(11): 1488–1488, doi: 
10.1182/blood.v108.11.1488.1488.
13. Needleman L, Cronan J, Lilly M, et al. Ultrasound for lower 
extremity deep venous thrombosis. Circulation. 2018; 137(14): 
1505–1515, doi: 10.1161/circulationaha.117.030687.
14. Kearon C, Kearon C. Natural history of venous thrombo-
embolism. Circulation. 2003; 107(23 Suppl 1): I22–I30, doi: 
10.1161/01.CIR.0000078464.82671.78, indexed in Pubmed: 
12814982.
15. Sevestre MA, Quashié C, Genty C, et al. Clinical presenta-
tion and mortality in pulmonary embolism: The Optimev study. 
Journal des Maladies Vasculaires. 2010; 35(4): 242–249, doi: 
10.1016/j.jmv.2010.05.004.
16. Galanaud JP, Quenet S, Rivron-Guillot K, et al. RIETE INVES-
TIGATORS. Comparison of the clinical history of symptomatic 
isolated distal deep-vein thrombosis vs. proximal deep vein 
thrombosis in 11 086 patients. J Thromb Haemost. 2009; 7(12): 
2028–2034, doi: 10.1111/j.1538-7836.2009.03629.x, indexed in 
Pubmed: 19793188.
17. Fleck D, Albadawi H, Wallace A, et al. Below-knee deep vein 
thrombosis (DVT): diagnostic and treatment patterns. Cardio-
vasc Diagn Ther. 2017; 7(Suppl 3): S134–S139, doi: 10.21037/
cdt.2017.11.03, indexed in Pubmed: 29399516.
18. Garry J, Duke A, Labropoulos N. Systematic review of the 
complications following isolated calf deep vein thrombosis. Br J 
Surg. 2016; 103(7): 789–796, doi: 10.1002/bjs.10152, indexed 
in Pubmed: 27060255.
19. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for 
VTE disease: CHEST guideline and expert panel report. Chest. 
2016; 149(2): 315–352, doi: 10.1016/j.chest.2015.11.026, in-
dexed in Pubmed: 26867832.
20. Galanaud JP, Sevestre MA, Genty C, et al. OPTIMEV-SFMV 
investigators. Incidence and predictors of venous thromboem-
bolism recurrence after a first isolated distal deep vein throm-
bosis. J Thromb Haemost. 2014; 12(4): 436–443, doi: 10.1111/
jth.12512, indexed in Pubmed: 24450376.
21. Sartori M, Migliaccio L, Favaretto E, et al. Two years outcome 
of isolated distal deep vein thrombosis. Thromb Res. 2014; 
134(1): 36–40, doi: 10.1016/j.thromres.2014.03.033, indexed 
in Pubmed: 24713107.
22. Barco S, Corti M, Trinchero A, et al. Survival and recurrent 
venous thromboembolism in patients with first proximal or iso-
lated distal deep vein thrombosis and no pulmonary embolism. 
J Thromb Haemost. 2017; 15(7): 1436–1442, doi: 10.1111/
jth.13713, indexed in Pubmed: 28439954.
23. Galanaud JP, Monreal M, Kahn SR, et al. Epidemiology of the 
post-thrombotic syndrome. Thromb Res. 2018(164): 100–109.
24. Meissner MH, Caps MT, Bergelin RO, et al. Early outcome 
after isolated calf vein thrombosis. J Vasc Surg. 1997; 26(5): 
749–756, doi: 10.1016/s0741-5214(97)70086-7, indexed in Pu-
bmed: 9372811.
25. Saarinen JP, Domonyi K, Zeitlin R, et al. Postthrombotic syn-
drome after isolated calf deep venous thrombosis: the role of 
popliteal reflux. J Vasc Surg. 2002; 36(5): 959–964, doi: 10.1067/
mva.2002.127523, indexed in Pubmed: 12422091.
26. McLafferty RB, Moneta GL, Passman MA, et al. Late clinical and 
hemodynamic sequelae of isolated calf vein thrombosis. J Vasc 
Surg. 1998; 27(1): 50–56; discussion 56, doi: 10.1016/s0741-
5214(98)70291-5, indexed in Pubmed: 9474082.
27. Galanaud JP, Righini M, Le Collen L, et al. Long-term risk of 
postthrombotic syndrome after symptomatic distal deep vein 
thrombosis: The CACTUS-PTS study. J Thromb Haemost. 
2020; 18(4): 857–864, doi: 10.1111/jth.14728, indexed in Pu-
bmed: 31899848.
28. Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for 
venous thromboembolic disease: American College of Chest 
Physicians Evidence-Based Clinical Practice Guidelines (8th Edi-
tion). Chest. 2008; 133(6 Suppl): 454S–545S, doi: 10.1378/
chest.08-0658, indexed in Pubmed: 18574272.
29. Kahn SR, Shapiro S, Wells PS, et al. SOX trial investigators. Compres-
sion stockings to prevent post-thrombotic syndrome: a randomised 
placebo-controlled trial. Lancet. 2014; 383(9920): 880–888, doi: 
10.1016/S0140-6736(13)61902-9, indexed in Pubmed: 24315521.
30. Palareti G. How I Treat isolated distal DVT. Blood. 2015; 123: 
1802–1810.
31. Pinede L, Ninet J, Duhaut P, et al. Investigators of the “Durée 
Optimale du Traitement AntiVitamines K” (DOTAVK) Study. 
Comparison of 3 and 6 months of oral anticoagulant therapy 
after a first episode of proximal deep vein thrombosis or pul-
monary embolism and comparison of 6 and 12 weeks of ther-
apy after isolated calf deep vein thrombosis. Circulation. 2001; 
103(20): 2453–2460, doi: 10.1161/01.cir.103.20.2453, indexed 
in Pubmed: 11369685.
32. Ferrara F, Meli F, Amato C, et al. Optimal duration of treat-
ment in surgical patients with calf venous thrombosis involv-
ing one or more veins. Angiology. 2006; 57(4): 418–423, doi: 
10.1177/0003319706290745, indexed in Pubmed: 17022376.
33. Franco L, Giustozzi M, Agnelli G, et al. Anticoagulation in pa-
tients with isolated distal deep vein thrombosis: a meta-analysis. 
J Thromb Haemost. 2017; 15(6): 1142–1154, doi: 10.1111/
jth.13677, indexed in Pubmed: 28316124.
34. Schwarz T, Buschmann L, Beyer J, et al. Therapy of isolated calf 
muscle vein thrombosis: a randomized, controlled study. J Vasc 
Surg. 2010; 52(5): 1246–1250, doi: 10.1016/j.jvs.2010.05.094, 
indexed in Pubmed: 20630682.
35. Righini M, Galanaud JP, Guenneguez H, et al. Anticoagulant 
therapy for symptomatic calf deep vein thrombosis (CACTUS): 
a randomised, double-blind, placebo-controlled trial. Lancet 
Haematol. 2016; 3(12): e556–e562, doi: 10.1016/S2352-
3026(16)30131-4, indexed in Pubmed: 27836513.
36. Kirkilesis G, Kakkos SK, Bicknell C, et al. Treatment of distal 
deep vein thrombosis. Cochrane Database Syst Rev. 2020; 4: 
CD013422, doi: 10.1002/14651858.CD013422.pub2, indexed 
in Pubmed: 32271939.
